LAB
Standard BioTools Inc. · Healthcare · Medical - Specialties
Momentum inputs (comparable managers):
holder breadth -20.0% ·
share flow -1.8% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 63 | -12 | 121.60M | $100.00M | +9 | −21 |
| Q1 2026 | 78 | -1 | 139.51M | $128.36M | +4 | −5 |
| Q4 2025 | 78 | +1 | 157.79M | $201.97M | +1 | — |
| Q3 2025 | 15 | 0 | 128.39M | $166.92M | — | — |
| Q2 2025 | 12 | +1 | 121.19M | $145.43M | +1 | — |
| Q1 2025 | 8 | -2 | 82.05M | $88.62M | — | −2 |
| Q4 2024 | 10 | -2 | 83.56M | $146.24M | — | −2 |
| Q3 2024 | 11 | 0 | 85.39M | $164.80M | — | — |
| Q2 2024 | 11 | — | 90.16M | $159.59M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 58.65M | 0.0% | $63.34M | 0.2% | Held | 4 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 7.21M | +3.3% | $7.78M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 7.21M | +3.3% | $7.78M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 6.36M | +1.1% | $6.87M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Millennium Management ✦ | 5.07M | -28.4% | $5.48M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | ARK Investment Management ✦ | 3.45M | +3.9% | $3.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 632.07K | -1.5% | $682,640 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 482.91K | +862.2% | $521,545 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 482.91K | +862.2% | $521,545 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 482.91K | +862.2% | $521,545 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 482.91K | +862.2% | $521,545 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 482.91K | +862.2% | $521,545 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 195.47K | +7.7% | $212,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $502,147 | was 0.0% |
| Citadel Advisors | $142,781 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 154 holders, 297.10M shares, $272.49M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
15.0% of class · View original SEC filing ↗
22.7% of class · View original SEC filing ↗